TTK Healthcare
LIMITED

TTKH:SECL:GJ:077:16 **May 30, 2016**

National Stock Exchange of India Limited (NSE)
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400 051

Scrip Code : TTKHLTCARE

Dear Sirs,

Re : Audited Financial Results for the year ended 31st March, 2016

We are forwarding herewith the Audited Financial Results for the year ended 31st March, 2016, along with the Audit Report, Form A and Declaration taken on record by the Board of Directors of the Company at their Meeting held today at Chennai.

Kindly take the above document on record.

Thanking you

Yours faithfully
For TTK Healthcare Limited

(S KALYANARAMAN)
Director & Wholetime Secretary

Encl. : a/a

Regd. Office : No. 6, Cathedral Road, Chennai - 600 086, INDIA
Phone : 91-44-28116106 - 08, Fax : 91-44-28116387
Email : info@ttkhealthcare.com Website : www.ttkhealthcare.com
CIN : L24231TN1958PLC003647
(Factory : 5, Old Trunk Road, Pallavaram Chennai - 600 043, INDIA)

TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED 31st MARCH, 2016

(Rs. in lakhs)

Sl. No.	Particulars	3 months ended	Preceding 3 months ended	Corres-ponding 3 months ended in the previous year	Current Year ended	Previous Year ended
		(31/03/2016)	(31/12/2015)	(31/03/2015)	(31/03/2016)	(31/03/2015)
		Unaudited	Unaudited	Unaudited	Audited	Audited
1.	Income from Operations					
	(a) Net Sales / Income from Operations (Net of Excise Duty)	11956.76	12682.63	11169.66	51480.01	48254.73
	(b) Other Operating Income	3.44	395.42	20.35	406.54	37.93
	Total income from Operations (Net)	**11960.20**	**13078.05**	**11190.01**	**51886.55**	**48292.66**
2.	Expenses					
	(a) Cost of materials consumed	1025.01	864.48	703.45	3547.32	3138.64
	(b) Purchases of Stock-in-trade	4703.78	4602.53	4214.03	19525.48	19063.03
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-472.26	196.01	14.02	-145.66	-256.89
	(d) Employee benefits expense	2124.46	2038.95	1899.30	8179.87	7228.44
	(e) Depreciation and amortisation expense	265.35	146.08	247.22	720.71	613.98
	(f) Marketing Expenses	1182.43	1925.65	1355.70	7685.67	7961.59
	(g) Other expenses	2334.84	2196.54	2102.47	9046.90	8202.96
	Total Expenses	**11163.61**	**11970.24**	**10536.19**	**48560.29**	**45951.75**
3.	**Profit / (Loss) from Operations before Other Income, Finance Costs and Exceptional Items (1-2)**	**796.59**	**1107.81**	**653.82**	**3326.26**	**2340.91**
4.	Other Income	160.52	124.94	201.40	559.21	656.78
5.	**Profit / (Loss) from Ordinary Activities before Finance Costs and Exceptional Items (3±4)**	**957.11**	**1232.75**	**855.22**	**3885.47**	**2997.69**
6.	Finance Costs	114.14	71.09	96.37	332.73	364.23
7.	**Profit / (Loss) from Ordinary Activities after Finance Costs but before Exceptional Items (5±6)**	**842.97**	**1161.66**	**758.85**	**3552.74**	**2633.46**
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00
9.	**Profit / (Loss) from Ordinary Activities before Tax (7±8)**	**842.97**	**1161.66**	**758.85**	**3552.74**	**2633.46**
10.	Tax Expense	248.70	432.55	302.05	1286.22	1017.94
11.	**Net Profit / (Loss) from Ordinary Activities after Tax (9±10)**	**594.27**	**729.11**	**456.80**	**2266.52**	**1615.52**
12.	Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00	0.00
13.	**Net Profit / (Loss) for the period (11±12)**	**594.27**	**729.11**	**456.80**	**2266.52**	**1615.52**
14.	Share of Profit / (Loss) of Associates	N.A.	N.A.	N.A.	N.A.	N.A.
15.	Minority Interest	N.A.	N.A.	N.A.	N.A.	N.A.
16.	**Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13±14±15)**	**594.27**	**729.11**	**456.80**	**2266.52**	**1615.52**

17.	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	776.60	776.60	776.60	776.60	776.60
18.	Reserve excluding Revaluation Reserves as per Balance Sheet of previous accounting year				12403.18	10604.00
19 (i)	**Earnings per share (before Extraordinary Items) (of Rs.10/- each) (not annualised):**					
	(a) Basic	7.65	9.39	5.88	29.19	20.80
	(b) Diluted	7.65	9.39	5.88	29.19	20.80
19 (ii)	**Earnings per share (after Extraordinary Items) (of Rs.10/- each) (not annualised):**					
	(a) Basic	7.65	9.39	5.88	29.19	20.80
	(b) Diluted	7.65	9.39	5.88	29.19	20.80

NOTES:

(1) The above results have been reviewed / audited by the Statutory Auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors of the Company at their Meeting held on 30th May, 2016, at Chennai.

(2) The Other Operating Income for the current year includes non-recurring income of Rs.3.25 crores (Net) received during the Third Quarter towards product development trials conducted for a Third Party.

(3) The Board has recommended a Dividend of Rs.5.00 per Equity Share of Rs.10/- each (50%) for the financial year ended 31st March, 2016.

(4) The figures for the three months' ended 31st March, 2016 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the nine months of the relevant financial year.

(5) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

(6) This Statement is also available on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

(7)	Standalone Statement of Assets and Liabilities as at 31st March, 2016:		
Sl. No.	Particulars	As at 31/03/2016 Rs.	As at 31/03/2015 Rs.
A	**EQUITY AND LIABILITIES**		
1.	**Shareholders' Funds**		
	(a) Share Capital	77659830	77659830
	(b) Reserves and Surplus	1284460632	1105045079
	(c) Money received against Share Warrants	0	0
	Sub-Total - Shareholders' Funds	**1362120462**	**1182704909**
2.	**Share Application Money pending allotment**	0	0
3.	**Minority Interest**	0	0
4.	**Non-Current Liabilities**		
	(a) Long-Term Borrowings	10609632	159836379
	(b) Deferred Tax Liabilities (Net)	50680409	22258779
	(c) Other Long-Term Liabilities	102451721	96564362
	(d) Long-Term Provisions	0	0
	Sub-Total - Non-Current Liabilities	**163741762**	**278659520**
5.	**Current Liabilities**		
	(a) Short-Term Borrowings	219531330	223012201
	(b) Trade Payables	333740251	300688951
	(c) Other Current Liabilities	899302473	724732163
	(d) Short-Term Provisions	46839759	42166265
	Sub-Total - Current Liabilities	**1499413813**	**1290599580**
	TOTAL - EQUITY AND LIABILITIES	**3025276037**	**2751964009**
B	**ASSETS**		
1.	**Non-Current Assets**		
	(a) Fixed Assets	1070704107	975720790
	(b) Goodwill on Consolidation	0	0
	(c) Non-Current Investments	0	0
	(d) Deferred Tax Assets (Net)	0	0
	(e) Long-Term Loans and Advances	118926017	115245388
	(f) Other Non-Current Assets	0	0
	Sub-Total - Non-Current Assets	**1189630124**	**1090966178**
2.	**Current Assets**		
	(a) Current Investments	101337000	1337000
	(b) Inventories	414526066	373774375
	(c) Trade Receivables	466202804	444125976
	(d) Cash and Cash Equivalents	771629009	772998464
	(e) Short-Term Loans and Advances	81951034	68762016
	(f) Other Current Assets	0	0
	Sub-Total - Current Assets	**1835645913**	**1660997831**
	TOTAL - ASSETS	**3025276037**	**2751964009**

For TTK HEALTHCARE LIMITED

Place: Chennai
Date: May 30, 2016

T T RAGHUNATHAN
EXECUTIVE VICE CHAIRMAN

TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

SEGMENTWISE REVENUE, RESULTS & CAPITAL EMPLOYED

(Rs. in lakhs)

Sl. No.	Particulars	3 months ended	Previous 3 months ended	Corres-ponding 3 months ended in the previous year	Current year ended	Previous Year ended
		(31/03/2016) Unaudited	(31/12/2015) Unaudited	(31/03/2015) Unaudited	(31/03/2016) Audited	(31/03/2015) Audited
1.	**Segment Revenue:**					
	(a) Pharmaceuticals	6260.29	6702.85	6119.70	27665.54	26275.27
	(b) Medical Devices	579.55	496.73	468.26	2251.06	1979.64
	(c) Consumer Products	3278.36	3989.63	3131.64	15406.46	14215.38
	(d) Foods	1809.75	1485.06	1436.95	6069.32	5712.28
	(e) Others	28.81	8.36	13.11	87.63	72.16
Total		**11956.76**	**12682.63**	**11169.66**	**51480.01**	**48254.73**
Less : Inter Segment Revenue		0.00	0.00	0.00	0.00	0.00
Net Sales / Income from Operations		**11956.76**	**12682.63**	**11169.66**	**51480.01**	**48254.73**
2.	**Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]**					
	(a) Pharmaceuticals	880.67	832.52	750.10	3117.82	2510.23
	(b) Medical Devices	175.23	46.35	123.76	393.43	301.89
	(c) Consumer Products	-40.90	74.33	-151.31	115.64	-543.65
	(d) Foods	93.74	462.01	291.19	915.63	1236.83
	(e) Others	6.12	4.12	6.87	31.89	26.25
Total		**1114.86**	**1419.33**	**1020.61**	**4574.41**	**3531.55**
Less : Interest		114.14	71.09	96.37	332.73	364.23
Less : Unallocable Expenses (Net of Unallocable Income)		157.75	186.58	165.39	688.94	533.86
Total Profit (+) / Loss (-) before tax		**842.97**	**1161.66**	**758.85**	**3552.74**	**2633.46**
3.	**Capital Employed (Segment Assets - Segment Liabilities)**	**As on 31/03/2016**	**As on 31/12/2015**	**As on 31/03/2015**	**As on 31/03/2016**	**As on 31/03/2015**
	(a) Pharmaceuticals	-84.67	478.72	1048.98	-84.67	1048.98
	(b) Medical Devices	1457.55	1186.33	1228.77	1457.55	1228.77
	(c) Consumer Products	-380.24	-124.86	-253.16	-380.24	-253.16
	(d) Foods	9634.58	8546.22	7700.97	9634.58	7700.97
	(e) Others	-39.08	-46.76	-21.10	-39.08	-21.10
Total Capital Employed in Segments		**10588.14**	**10039.65**	**9704.46**	**10588.14**	**9704.46**
Add : Unallocable Corporate Assets **less** Unallocable Corporate Liabilities		6221.81	6342.02	6782.55	6221.81	6782.55
Total Capital Employed in Company		**16809.95**	**16381.67**	**16487.01**	**16809.95**	**16487.01**

NOTES:

1. Segments have been identified in line with the Accounting Standard on Segment Reporting (AS-17) considering the organisation structure and the differential risks and returns of these segments.
2. Segment Sales is net of Excise Duty related to the Sales of own manufactured goods for the current as well as for the previous periods.
3. Details of products included in each of the Segments are as below :
   - ❖ Pharmaceuticals include products for both Human and Veterinary use. It also includes OTC Brands like Woodward's Gripewater distributed by the Consumer Products Division.
   - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
   - ❖ Consumer Products comprise of marketing and distribution of EVA Range of Cosmetics, Good Home range of Scrubbers, Air Freshners, etc., (Own Brands) and also trading of Branded Condoms.
   - ❖ Foods comprise of manufacturing and marketing of Food Products.
   - ❖ "Others" include Printing and Publishing of Maps and Atlases.
4. The segment-wise revenue, results and capital employed figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
5. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

Place : Chennai
Date : May 30, 2016

T T RAGHUNATHAN
EXECUTIVE VICE CHAIRMAN

INDEPENDENT AUDITORS
REPORT TO THE BOARD OF DIRECTORS OF TTK HEALTHCARE LIMITED

1. We have audited the accompanying Statement of Financial Results of TTK Healthcare Limited ("the Company") for the year ended 31st March, 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ["the SEBI (LODR) Regulations, 2015"]. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of the related financial statements, which is in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013, as applicable and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement.

2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

   An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

   We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

3. In our opinion and to the best of our information and according to the explanations given to us, the Statement, read with Note 4:
   (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015; and
   (ii) gives a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the net profit and other financial information of the Company for the year ended 31st March, 2016.

4. This Statement includes the results for the Quarter ended 31st March, 2016 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the Third Quarter of the current financial year which were subject to limited review by us.

For M/s Aiyar & Co.
Chartered Accountants
F.R. No.000063S

N SRIDHARAN
PROPRIETOR
Membership No.20503

For M/s S Viswanathan LLP
Chartered Accountants
F.R. No.004770S / S200025

C N SRINIVASAN
PARTNER
Membership No.18205

Place : Chennai
Date : May 30, 2016

TTK Healthcare
LIMITED

FORM A

As per Regulations 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of the Company	**TTK Healthcare Limited**
2.	Annual Financial Statements for the year ended	**31st March, 2016**
3.	Type of Audit Observation	**(i) Unmodified** **(ii) Matter of Emphasis** - Proposed Scheme of Amalgamation between M/s TTK Protective Devices Limited (formerly known as TTK-LIG Limited) and its Wholly Owned Subsidiary M/s TSL Techno Services Limited (TSL) [Transferor Companies] with the Company [Transferee Company]
4.	Frequency of Observation	**Matter of Emphasis - Fourth time (Since the Merger is yet to be sanctioned by the Hon'ble High Court of Judicature at Madras).**
5.	Signed by-	
	CEO / Managing Director	**(T T RAGHUNATHAN)** *Executive Vice Chairman*
	CFO	**(B V K DURGA PRASAD)** *Senior Vice President - Finance*
	Auditors of the Company	**(N SRIDHARAN)** *Proprietor* **M/s Aiyar & Co.**
		(C N SRINIVASAN) *Partner* **M/s S Viswanathan LLP**
	Audit Committee Chairman	**(GIRISH RAO)** *Chairman* **Audit Committee**

Regd. Office : No. 6, Cathedral Road, Chennai - 600 086, INDIA
Phone : 91-44-28116106 - 08, Fax : 91-44-28116387
Email : info@ttkhealthcare.com Website : www.ttkhealthcare.com
CIN : L24231TN1958PLC003647
(Factory : 5, Old Trunk Road, Pallavaram Chennai - 600 043, INDIA)

TTK Healthcare
LIMITED

TTKH:SECL:GJ:079:16 **May 30, 2016**

National Stock Exchange of India Limited (NSE)
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400 051

Scrip Code : TTKHLTCARE

Dear Sirs,

Sub: Declaration relating to the Unmodified Opinion by the Statutory Auditors on the Audited Financial Statements for the year ended 31st March, 2016

Ref: (i) Regulation 33(3)(d) to the SEBI (LODR) Regulations, 2015
(ii) Notification dated 25th May, 2016 issued by SEBI
(iii) Circular No.CIR/CFD/CMD/56/2016 dated 27th May, 2016 issued by SEBI

We hereby declare that the Statutory Auditors of the Company have given their **Unmodified Opinion** to the Audited Financial Statements of the Company for the year ended 31st March, 2016.

Their Report also includes an "Emphasis of Matters" relating to the proposed Scheme of Amalgamation between M/s TTK Protective Devices Limited (formerly known as TTK-LIG Limited) and its Wholly Owned Subsidiary M/s TSL Techno Services Limited (TSL) [Transferor Companies] with the Company [Transferee Company] which is awaiting the sanction of the Hon'ble High Court of Judicature at Madras.

Please take the above information on record.

Thanking you

Yours faithfully
For TTK Healthcare Limited

(T T RAGHUNATHAN)
Executive Vice Chairman

Regd. Office : No. 6, Cathedral Road, Chennai - 600 086, INDIA
Phone : 91-44-28116106 - 08, Fax : 91-44-28116387
Email : info@ttkhealthcare.com Website : www.ttkhealthcare.com
CIN : L24231TN1958PLC003647
(Factory : 5, Old Trunk Road, Pallavaram Chennai - 600 043, INDIA)